BUZZ-Ionis drops after forecasting 2026 revenue below expectations

Reuters02-25

** Shares of drugmaker Ionis Pharmaceuticals IONS.O fall 6.4% to $80 premarket

** Co forecasts 2026 revenue between $800 million and $825 million, below analysts' average expectation of $902 million

** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter

** Co reports Q4 loss of $1.41/shr vs analysts' average loss estimate of $1.32/shr

** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million

** Up to last close, stock up 8% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614008499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614008499","market":"nz","top_or_hot":-1,"title":"BUZZ-Ionis drops after forecasting 2026 revenue below expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Ionis drops after forecasting 2026 revenue below expectations</title></head><body><p>** Shares of drugmaker Ionis Pharmaceuticals <span>IONS.O</span> fall 6.4% to $80 premarket</p><p>** <span>Co forecasts 2026 revenue </span>between $800 million and $825 million, below analysts' average expectation of $902 million</p><p>** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter</p><p>** Co reports <span>Q4 loss </span>of $1.41/shr vs analysts' average loss estimate of $1.32/shr</p><p>** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million</p><p>** Up to last close, stock up 8% YTD</p><p> (Reporting by Christy Santhosh)</p><p> ((Christy.Santhosh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Ionis drops after forecasting 2026 revenue below expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Ionis drops after forecasting 2026 revenue below expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 20:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Ionis drops after forecasting 2026 revenue below expectations</title></head><body><p>** Shares of drugmaker Ionis Pharmaceuticals <span>IONS.O</span> fall 6.4% to $80 premarket</p><p>** <span>Co forecasts 2026 revenue </span>between $800 million and $825 million, below analysts' average expectation of $902 million</p><p>** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter</p><p>** Co reports <span>Q4 loss </span>of $1.41/shr vs analysts' average loss estimate of $1.32/shr</p><p>** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million</p><p>** Up to last close, stock up 8% YTD</p><p> (Reporting by Christy Santhosh)</p><p> ((Christy.Santhosh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4N3ZL140:1","article_id":"2614008499","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614008499","pubTimestamp":1772023021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Ionis drops after forecasting 2026 revenue below expectations** Shares of drugmaker Ionis Pharmaceuticals IONS.O fall 6.4% to $80 premarket** Co forecasts 2026 revenue between $800 million and $825 million, below analysts' average expectation of $902 million** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter** Co reports Q4 loss of $1.41/shr vs analysts' average loss estimate of $1.32/shr** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million** Up to last close, stock up 8% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"BUZZ-Ionis预测2026年收入低于预期后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"BUZZ-Ionis drops after forecasting 2026 revenue below expectations** Shares of drugmaker Ionis Pharmaceuticals IONS.O fall 6.4% to $80 premarket** Co forecasts 2026 revenue between $800 million and $825 million, below analysts' average expectation of $902 million** IONS' genetic disorder drug Tryngolza generated $50 million in sales in Q4, a 56% increase over the prior quarter** Co reports Q4 loss of $1.41/shr vs analysts' average loss estimate of $1.32/shr** IONS' quarterly revenue of $203 million beats analysts' estimate of $156.1 million** Up to last close, stock up 8% YTD (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614008499","isCrawlerRequest":true}